Dopamine in behavioral state control

Neurochemistry of Sleep and Wakefulness

Volumn , Issue , 2008, Pages 179-223

  Rye, David B ^a   Freeman, Amanda A H ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84932643729     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511541674.008     Document Type: Chapter

References (282)

1. Abe M., Herzog E. D., Yamazaki S. et al. (2002). Circadian rhythms in isolated brain regions. J. Neurosci. 22(1), 350-6.
2. Agid Y. (1991). Parkinson's disease: pathophysiology. Lancet. 337, 1321-4.
3. Albin R., Koeppe R., Chervin R. et al. (2000). Decreased striatal dopaminergic innervation in REM sleep behavior disorder. Neurology. 55, 1410-12.
4. Albin R., Young A., Penney J. (1989). The functional anatomy of basal ganglia disorders. Trends Neurosci. 12, 366-75.
5. Albrecht D., Quäschling U., Zippel U., Davidowa H. (1996). Effects of dopamine on neurons of the lateral geniculate nucleus: an iontophoretic study. Synapse. 23, 70-8.
6. Alex K., Yavanian G., McFarlane H., Pluto C., Pehek E. (2005). Modulation of dopamine release by striatal 5-HT2C receptors. Synapse. 55, 242-51.
7. Alexander G. (1997). Anatomy of the basal ganglia and related motor structures. In: Watts R., Koller W., editors. Movement Disorders: Neurologic Principles and Practice. New York, NY: McGraw-Hill. pp. 73-86.
8. Alexander G. E., Crutcher M. D., DeLong M. R. (1990). Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions. Prog. Brain Res. 85, 119-46.
9. Alexander G. E., DeLong M. R., Strick P. L. (1986). Parallel organization of functionally segregated circuits linking basal ganglia and cortex. A. Rev. Neurosci. 9, 357-81.
10. Almirall H., Bautista V., Sanchez-Bahillo A., Trinidad-Herrero M. (2001). Ultradian and circadian body temperature and activity rhythms in chronic MPTP treated monkeys. Neurophysiol. Clin. 31, 161-70.
11. Andreau N., Chale J., Senard J. et al. (1999). L-dopa induced sedation: a double-blind cross-over controlled study versus triazolam and placebo in healthy volunteers. Clin. Neuropharmacol. 22, 15-23.
12. Andretic R., Hirsh J. (2000). Circadian modulation of dopamine receptor responsiveness in Drosophila melanogaster. Proc. Natl. Acad. Sci. USA 97(4), 1873-8.
13. Andretic R., van Swinderen B., Greenspan R. J. (2003). Dopaminergic modulation of arousal in Drosophila. Curr. Biol. 15(13), 1165-75.
14. Arnulf I., Bonnet A., Damier P. et al. (2000). Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis. Neurology 55(2), 281-8.
15. Arnulf I., Konofal E., Merino-Andreu M. et al. (2002). Parkinson's disease and sleepiness: an integral part of PD. Neurology. 58, 1019-24.
16. Arnulf I. (2005). Excessive daytime sleepiness in parkinsonism. Sleep Med. Rev. 9, 185-200.
17. Asakura W., Matsumoto K., Ohta H., Watanabe H. (1992). REM sleep deprivation decreases apomorphine-induced stimulation of locomotor activity but not stereotyped behavior in mice. Gen. Pharmacol. 23, 337-41.
18. Bagetta G., Sarro G. D., Priolo E., Nisticó G. (1988). Ventral tegmental area: site through which dopamine D2-receptor agonists evoke behavioral and electrocortical sleep in rats. Br. J. Pharmacol. 95, 860-6.
19. Bandmann O., Valente E., Holmans P. et al. (1998). Dopa-responsive dystonia: a clinical and molecular genetic study. Ann. Neurol. 44, 649-56.
20. Barbeau H., Rossignol S. (1991). Initiation and modulation of the locomotor pattern in the adult chronic spinal cat by noradrenergic, serotonergic and dopaminergic drugs. Brain Res. 546(2), 250-60.
21. Barcia C., Bautista V., Sanchez-Bahillo A. et al. (2003). Circadian determinations of cortisol, prolactin and melatonin in chronic methyl-phenyl-tetrahydropyridinetreated monkeys. Neuroendocrinology 78, 118-28.
22. Baumann C., Dauvilliers Y., Mignot E., Bassetti C. (2004). Normal CSF hypocretin-1 (orexin A) levels in dementia with Lewy bodies associated with excessive daytime sleepiness. Eur. Neurol. 52, 73-6.
23. Baumann C., Ferini-Strambi L., Waldvogel D., Werth E., Bassetti C. (2005). Parkinsonism with excessive daytime sleepiness - a narcolepsy like disorder? J. Neurol. 252, 139-45.
24. Behrends J., Prank K., Dogu E., Brabant G. (1998). Central nervous system control of thyrotropin secretion during sleep and wakefulness. Horm. Res. 49, 173-7.
25. Benker G., Jaspers C., Hausler G., Reinwein D. (1990). Control of prolactin secretion. Klin. Wochenschr. 68, 1157-67.
26. Berlanga M., Simpson T., Alcantra A. (2005). Dopamine D5 receptor localization on cholinergic neurons of the rat forebrain and diencephalon: a potential neuroanatomical substrate involved in mediating dopaminergic influences on acetylcholine release. J. Comp. Neurol. 492, 34-49.
27. Berridge C., O'Neil J., Wifler K. (1999). Amphetamine acts within the medial basal forebrain to initiate and maintain alert waking. Neuroscience 93, 885-96.
28. Besharse J., Zhunag M., Freeman K., Fogerty J. (2004). Regulation of photoreceptor Per1 and Per2 by light, dopamine and a circadian clock. Eur. J. Neurosci. 20, 167-4.
29. Bjorklund A, Lindvall O. (1984). Dopamine-containing systems in the CNS. In: Bjorklund A., Hokfelt T., editors. Handbook of Chemical Neuroanatomy. Amsterdam: Elsevier. pp. 55-122.
30. Bjorklund A., Skagerberg G. (1979). Evidence for a major spinal cord projection from the diencephalic A11 dopamine cell group in the rat using transmitter-specific fluorescent retrograde tracing. Brain Res. 177(1), 170-5.
31. Blackburn T., Suzuki K., Ashby C., Jr. (2006). The acute and chronic administration of the 5-HT (2B/2C) receptor antagonist SB-200646A significantly alters the activity of spontaneously active midbrain dopamine neurons in the rat: an in vivo extracellular single cell study. Synapse. 59, 502-12.
32. Bliwise D., Rye D., Dihenia B. et al. (1998). Periodic leg movements in elderly patients with Parkinsonism. Sleep 21(Suppl.), 196.
33. Bliwise D., Rye D., He L., Ansari F. (2003). Influence of PLMs on scoring phasic leg muscle activity. Sleep 26, A344.
34. Boeve B., Silber M., Ferman T. et al. (1998). REM sleep behavior disorder and degenerative dementia - An association likely reflecting Lewy body disease. Neurology 51, 363-70.
35. Boeve B., Silber M., Pirisi J. et al. (2003). Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism. Neurology 61, 40-5.
36. Borland L. M., Michael A. C. (2004). Voltammetric study of the control of striatal dopamine release by glutamate. J. Neurochem. 91(1), 220-9.
37. Bortolozzi A., Diaz-Mataix L., Scorz M., Celada P., Artigas P. (2005). The activation of 5-HT receptors in prefrontal cortex enhances dopaminergic activity. J. Neurochem. 95, 1597-607.
38. Bourdelat-Parks B., Anderson G., Donaldson Z. et al. (2005). Effects of dopamine beta-hydroxylase genotype and disulfiram inhibition on catecholamine homeostasis in mice. Psychopharmacol. (Berl). 183, 72-80.
39. Braak H., Rub U., Sandmann-Keil D. et al. (2000). Parkinson's disease: affection of brain stem nuclei controlling premotor and motor neurons of the somatomotor system. Acta Neuropathol. (Berl.) 99, 489-95.
40. Braak H., Tredici K., Bratzke H. et al. (2002). Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J. Neurol. 249(Suppl. 3), III/1-IIII/5.
41. Braak H., Tredici K., Rub U. et al. (2003). Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197-211.
42. Brock J. W., Hamdi A., Ross K., Payne S., Prasad C. (1995). REM sleep deprivation alters dopamine D2 receptor binding in the rat frontal cortex. Pharmacol. Biochem. Behav. 52(1), 43-8.
43. Brodsky M., Godbold J., Roth T., Olanow C. (2003). Sleepiness in Parkinson's disease: a controlled study. Mov. Disord. 18, 668-72.
44. Bruinink A., Lichtensteiger W., Schlumpf M. (1983). Ontogeny of diurnal rhythms of central dopamine, serotonin and spirodecanone binding sites and of motor activity in the rat. Life Sci. 33(1), 31-8.
45. Bubser M., Fadel J., Jackson L. et al. (2005). Dopaminergic modulation of orexin neurons. Eur. J. Neurosci. 21, 2993-3001.
46. Calabrese E. (2001). Dopamine: biphasic dose responses. Crit. Rev. Toxicol. 31, 563-83.
47. Carboni E., Silvagni A. (2004). Dopamine reuptake by norepinephrine neurons: exception or rule? Crit. Rev. Neurobiol. 16, 121-8.
48. Carlsson A., Svennerholm L., Winblad B. (1980). Seasonal and circadian monoamine variations in human brain examined post mortem. Acta Pyschiatr. Scan. Suppl. 280, 275-5.
49. Castaneda T., de Prado B., Prieto D., Mora F. (2004). Circadian rhythms of dopamine, glutamate and GABA in the striatum and nucleus accumbens of the awake rat: modulation by light. J. Pineal Res. 36, 177-85.
50. Chergui K., Suaud-Chagny M. F., Gonon F. (1994). Nonlinear relationship between impulse flow, dopamine release and dopamine elimination in the rat brain in vivo. Neuroscience 62(3), 641-5.
51. Cianchetti C., Masala C., Olivari P., Giordano G. (1984). Sleep pattern alterations by naloxone. Partial prevention by haloperidol. Psychopharmacology (Berl). 83(2), 179-82.
52. Clemens S., Hochman S. (2004). Conversion of the modulatory actions of dopamine on spinal reflexes from depression to facilitation in D3 receptor knock-out mice. J. Neurosci. 24, 11337-45.
53. Clemens S., Rye D., Hochman S. (2006). Restless legs syndrome: revisiting the dopamine hypothesis from the spinal cord perspective. Neurology 67, 125-30.
54. Cobb W., Abercrombie E. (2003). Differential regulation of somatodendritic and nerve terminal release by serotonergic innervation of substantia nigra. J. Neurochem. 84, 576-84.
55. Comella C., Nardine T., Diederich N., Stebbins G. (1997). Sleep-related violence, injury, and REM sleep behavior disorder in Parkinson's disease. Neurology 48(3), A539.
56. Comella C., Tanner C., Ristanovic R. (1993). Polysomnographic sleep measures in Parkinson's Disease patients with treatment-induced hallucinations. Ann. Neurol. 34, 710-14.
57. Cooper J., Bloom F., Roth R. (2002). The Biochemical Basis of Neuropharmacology. 8th ed. New York: Oxford University Press.
58. Cornil C. A., Balthazart J., Motte P., Massotte L., Seutin V. (2002). Dopamine activates noradrenergic receptors in the preoptic area. J. Neurosci. 22(21), 9320-30.
59. Corvaja N., Doucet G., Bolam J. (1993). Ultrastructure and synaptic targets of the raphe-nigral projection in the rat. Neuroscience 55(2), 417-27.
60. Cragg S., Greenfield S. (1997). Differential autoreceptor control of somatodendritic and axon terminal dopamine release in substantia nigra, ventral tegmental area and striatum. J. Neurosci. 17, 5738-46.
61. Crochet S., Sakai K. (2003). Dopaminergic modulation of behavioral states in mesopontine tegmentum: a reverse microdialysis study in freely moving cats. Sleep 26, 801-6.
62. Crochet S., Sakai K. (1999). Effects of microdialysis application of monoamines on the EEG and behavioural states in the cat mesopontine tegmentum. Eur. J. Neurosci. 11(10), 3738-52.
63. Dahlstrom A., Fuxe K. (1964). Evidence for the existence of monoaminecontaining neurones in the central nervous system. I. Demonstration of monoamines in the cell bodies of brain stem neurones. Acta Physiol. Scand. (Suppl.) 232, 1-55.
64. Daley J., Turner R., Becker D., Bliwise D., Rye D. (1998). Telemetric recording of sleep in macaca mulatta prior to systemic MPTP. Sleep 21(Suppl.)(3), 6.
65. Daley J., Turner R., Bliwise D., Rye D. (1999). Nocturnal sleep and daytime alertness in the MPTP-treated primate. Sleep 22(Suppl.), S218-19.
66. Daley J. (2003). A Role for Dopamine in the Basal Ganglia in Sleep-Wake Regulation: Insights from the MPTP-Treated Primate. Atlanta, GA: Emory University.
67. Darracq L., Blanc G., Glowinski J., Tassin J. (1998). Importance of the noradrenalinedopamine coupling in the locomotor activating effects of D-amphetamine. J. Neurosci. 18, 2729-39.
68. Decker M., Keating G., Freeman A., Rye D. (2000). Parkinsonian-like sleep-wake architecture in rats with bilateral striatal 6-OHDA lesions. Soc. Neurosci. Abstr. 26, 1514.
69. Decker M. J., Keating G., Hue G. E., Freeman A., Rye D. B. (2002). Mesolimbic dopamine's modulation of REM Sleep. J. Sleep. Res. (suppl.) 51, 51-2.
70. DeLong M. R. (1990). Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 13, 281-5.
71. Devoto P., Flore G., Saba P., Fa M., Gessa G. (2005). Stimulation of the locus coeruleus elicits noradrenaline and dopamine release in the medial prefrontal and parietal cortex. J. Neurochem. 92, 368-74.
72. Di Matteo V., Cacchio M., Di Giulio C., Esposito E. (2002). Role of serotonin (2C) receptors in the control of brain dopaminergic function. Pharmacol. Biochem. Behav. 71, 727-34.
73. Doi M., Yujnovsky I., Hirayama J. et al. (2006). Impaired light masking in dopamine receptor-null mice. Nat. Neurosci. 9, 732-4.
74. Doyle S., Grace M., McIvor W. (2002). Menaker M. Circadian rhythms of dopamine in mouse retina: the role of melatonin. Vis. Neurosci. 19, 593-601.
75. Drouot X., Moutereau S., Nguyen J. et al. (2003). Low levels of ventricular CSF orexin/hypocretin in advanced PD. Neurology 61, 540-3.
76. Durán-Vázquez A., Drucker-Colín R. (1997). Differential role of dopamine receptors on motor asymmetries of nigro-stratal lesioned animals that are REM sleep deprived. Brain Res. 744, 171-4.
77. Durstewitz D., Kroner S., Gunturkun O. (1999). The dopaminergic innervation of the avian telencephalon. Prog. Neurobiol. 59(2), 161-95.
78. Edgar D. M., Dement W. C., Fuller C. A. (1993). Effect of SCN lesions on sleep in squirrel monkeys: evidence for opponent processes in sleep-wake regulation. J. Neurosci. 13(3), 1065-79.
79. Edgar D. M., Seidel W. F. (1997). Modafinil induces wakefulness without intensifying motor activity or subsequent rebound hypersomnolence in the rat. J. Pharmacol. Exp. Ther. 283(2), 757-69.
80. Eisensehr I., Linke R., Noachtar S. et al. (2000). Reduced striatal dopamine transporters in idiopathic rapid eye movement behaviour disorder. Comparison with Parkinson's disease and controls. Brain 123(6), 1155-60.
81. Ennis M., Zhou F., Ciombor K. et al. (2001). Dopamine D2 receptor-mediated presynaptic inhibition of olfactory nerve terminals. J. Neurophysiol. 86, 2986-97.
82. Evans H. L., Ghiselli W. B., Patton R. A. (1973). Diurnal rhythm in behavioral effects of methamphetamine, p-chloramethamphetamine and scopolamine. J. Pharmacol. Exp. Ther. 186(1), 10-17.
83. Fadda P., Martellotta M. C., De Montis M. G., Gessa G. L., Fratta W. (1992). Dopamine D1 and opioid receptor binding changes in the limbic system of sleep deprived rats. Neurochem. Int. 20 (Suppl.), 153S-156S.
84. Fadda P., Martellotta M. C., Gessa G. L., Fratta W. (1993). Dopamine and opioids: interactions in sleep deprivation. Prog. Neuropsychopharmacol. Biol. Psychiatry 17(2), 269-78.
85. Fantini M. L., Gagnon J. F., Filipini D., Montplaisir J. (2003). The effects of pramipexole in REM sleep behavior disorder. Neurology 61(10), 1418-20.
86. Farber J., Miller J. D., Crawford K. A., McMillen B. A. (1983). Dopamine metabolism and receptor sensitivity in rat brain after REM sleep deprivation. Pharmacol. Biochem. Behav. 18(4), 509-13.
87. Farooqui S. M., Brock J. W., Zhou J. (1996). Changes in monoamines and their metabolite concentrations in REM sleep-deprived rat forebrain nuclei. Pharmacol. Biochem. Behav. 54(2), 385-91.
88. Feenstra M., Botterblom M., Mastenbrook S. (2000). Dopamine and noradrenaline efflux in the prefrontal cortex in the light and dark period: effects of novelty and handling and comparison to the nucleus accumbens. Neuroscience 100, 741-8.
89. Ferreira J. J., Galitzky M., Thalamas C. et al. (2002). Effect of ropinirole on sleep onset: a randomized placebo controlled study in healthy volunteers. Neurology 58(3), 460-2.
90. Fibiger H., Phillips A. (1986). Reward, motivation, cognition: Psychobiology of mesotelencephalic dopamine systems. In: Handbook of Physiology, Vol. 4. Intrinsic regulatory systems of the brain. Bethesda, MD: American Physiology Society; pp. 647-75.
91. Fleetwood-Walker S., Hope P., Mitchell R. (1988). Antinociceptive actions of descending dopaminergic tracts on cat and rat dorsal horn somatosensory neurones. J. Physiol. Lond. 399, 335-48.
92. Floran B., Floran L., Erlij D., Aceves J. (2004). Activation of dopamine D4 receptors modulates [3H]GABA release in slices of the rat thalamic reticular nucleus. Neuropharmacology 46, 497-503.
93. Floresco S. B., West A. R., Ash B., Moore H., Grace A. A. (2003). Afferent modulation of dopamine neuron firing differentially regulates tonic and phasic dopamine transmission. Nat. Neurosci. 6(9), 968-73.
94. Forster G., Blaha C. (2000). Laterodorsal tegmental stimulation elicits dopamine efflux in the rat nucleus accumbens by activation of acetycholine and glutamate receptors in the ventral tegemental area. Eur J Neurosci 12, 3596-604.
95. Freeman A., Ciliax B., Bakay R. et al. (2001). Nigrostriatal collaterals to thalamus degenerate in parkinsonian animal models. Ann. Neurol. 50, 321-9.
96. Freeman A., Morales J., Beck J. et al. (2006). In vivo diurnal rhythm of dopamine measured in the putamen of non-human primates. Sleep 29(Abstr. Suppl.), A69.
97. Freeman A. (2006). Anatomy and Physiology of the Mesothalamic Dopamine System. Atlanta, GA: Emory University.
98. Gagnon J., Bedard M-A., Fantini M. et al. (2002). REM sleep behavior disorder and REM sleep without atonia in Parkinson's disease. Neurology 59, 585-9.
99. Garcia-Borreguero D., Larrosa O., Saiz T. et al. (2001). Circadian variation in neuroendocrine response to the administration of l-dopa in patients with restless legs syndrome: a pilot study. Sleep 24(suppl.), (A16-A17).
100. Gaspar P., Stepniewska I., Kaas J. H. (1992). Topography and collateralization of the dopaminergic projections to motor and lateral prefrontal cortex in owl monkeys. J. Comp. Neurol. 325(1), 1-21.
101. Gaykema R. P., Zaborszky L. (1996). Direct catecholaminergic-cholinergic interactions in the basal forebrain. II. Substantia nigra-ventral tegmental area projections to cholinergic neurons. J. Comp. Neurol. 374(4), 555-77.
102. Gaytan O., Swann A., Dafny N. (1998). Diurnal differences in rat's motor response to amphetamine. Eur. J. Pharmacol. 345(2), 119-28.
103. Georges F., Aston-Jones G. (2001). Potent regulation of midbrain dopamine neurons by the bed nucleus of the stria terminalis. J. Neurosci. 21(16), RC160.
104. Gerfen C. R., Herkenham M., Thibault J. (1987). The neostriatal mosaic: II. Patch- and matrix-directed mesostriatal dopaminergic and non-dopaminergic systems. J. Neurosci. 7, 3915-34.
105. Ghosh P. K., Hrdina P. D., Ling G. M. (1976). Effects of REMS deprivation on striatal dopamine and acetylcholine in rats. Pharmacol. Biochem. Behav. 4(4), 401-5.
106. Gillin C., Kammen D., Post R. et al. (1981). What is the role of dopamine in the regulation of sleep-wake activity? In: Corsini G., Gessa G., editors. Apomorphine and Other Dopaminomimetics. New York: Raven Press, pp. 157-64.
107. Gladwell S., Coote J. (1999). Inhibitory and indirect excitatory effects of dopamine on sympathetic preganglionic neurones in the neonate rat spinal cord in vitro. Brain Res. 818, 397-407.
108. Goldman-Rakic P. S. (1995). Cellular basis of working memory. Neuron 14(3), 477-85.
109. Govindaiah G., Cox C. (2006). Depression of retinogeniculate synaptic transmission by presynaptic D(2)-like dopamine receptors in rat lateral geniculate nucleus. Eur. J. Neurosci. 23, 423-34.
110. Govindaiah G., Cox C. (2005). Excitatory actions of dopamine via D1-like receptors in the rat lateral geniculate nucleus. J. Neurophysiol. 94, 3708-18.
111. Grace A., Bunney B. (1980). Nigral dopamine neurons: intracellular recording and identification with L-dopa injection and histofluorescence. Science Wash. DC 210, 654-6.
112. Greengard P., Allen P., Nairn A. (1999). Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Neuron 23, 435-7.
113. Grenhoff J., Janson A. M., Svensson T. H., Fuxe K. (1991). Chronic continuous nicotine treatment causes decreased burst firing of nigral dopamine neurons in rats partially hemitransected at the meso-diencephalic junction. Brain Res. 562, 347-51.
114. Grenhoff J., North R., Johnson S. (1995). Alpha 1-adrenergic effects on dopamine neurons recorded intracellularly in the rat midbrain slice. Eur. J. Neurosci. 7, 1707-13.
115. Griffond B., Risold P., Jacquemard C., Colard C., Fellmann D. (1999). Insulin-induced hypoglycemia increases preprohypocretin (orexin) mRNA in the rat lateral hypothalamic area. Neurosci. Lett. 262(2), 77-80.
116. Grillner S., Hellgren J., Menard A., Saitoh K., Wikstrom M. (2005). Mechanisms for selection of basic motor programs - roles for the striatum and pallidum. Trends Neurosci. 28, 364-70.
117. Gronier B., Rasmussen K. (1998). Activation of midbrain presumed dopaminergic neurons by muscarinic cholinergic receptors: an in vivo electrophysiological study in the rat. Br. J. Pharmacol. 124, 455-64.
118. Groves P. M., Wilson C. J., Young S. J., Rebec G. V. (1975). Self-inhibition by dopaminergic neurons. Science 190, 522-9.
119. Hagan M. M., Havel P. J., Seeley R. J. et al. (1999). Cerebrospinal fluid and plasma leptin measurements: covariability with dopamine and cortisol in fasting humans. J. Clin. Endocrinol. Metab. 84(10), 3579-85.
120. Halasz B., Fuxe K., Agnati L. F. et al. editors. (1985). The Dopaminergic System. New York, NY: Springer Verlag.
121. Hamdi A., Brock J., Ross K., Prasad C. (1993). Effects of rapid eye movement sleep deprivation on the properties of striatal dopaminergic system. Pharmacol. Biochem. Behav. 46, 863-6.
122. Hardman J., Limbird L., Goodman Gilman A. (2001). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York: McGraw-Hill Professional.
123. Henderson J., Carpenter K., Cartwright H., Halliday G. (2000a). Loss of thalamic intralaminar nuclei in progressive supranuclear palsy and Parkinson's disease: clinical and therapeutic implications. Brain 123(7), 1410-21.
124. Henderson J., Carpenter K., Cartwright H., Halliday G. (2000b). Degeneration of the centre median-parafascicular complex in Parkinson's disease. Ann. Neurol. 47(3), 345-52.
125. Heuer H., Schafer M., O'Donnell D., Walker P., Bauer K. (2000). Expression of thyrotropin-releasing hormone receptor 2 (TRH-R2) in the central nervous system of rats. J. Comp. Neurol. 428, 319-26.
126. Hobson D. E., Lang A. E., Martin W. R. W., Razmy A., Rivest J., Fleming J. (2002). Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease. JAMA 287(4), 455-63.
127. Hokfelt T., Martensson R., Bjorklund A., Kleinau S., Goldstein M. (1984). Distributional maps of tyrosine-hydroxylase-immunoreactive neurons in the rat brain. In: Bjorklund A., Hokfelt T., editors. Handbook of Chemical Neuroanatomy. New York: Elsevier; pp. 277-379.
128. Hokfelt T., Phillipson O., Goldstein M. (1979). Evidence for a dopaminergic pathway in the rat descending from the A11 cell group to the spinal cord. Acta Physiol. Scand. 107(4), 393-5.
129. Hue G., Decker M., Solomon I., Rye D. (2003). Increased wakefulness and hyperresponsivity to novel environments in mice lacking functional dopamine D3 receptors. In: Society for Neuroscience.
130. Iranzo A., Valldeoriola F., Santamaria J., Tolosa E., Rumia J. (2002). Sleep symptoms and polysomnographic architecture in advanced Parkinson's disease after chronic bilateral subthalamic stimulation. J. Neurol. Neurosurg. Psychiatry 72, 661-4.
131. Isaac S. O., Berridge C. W. (2003). Wake-promoting actions of dopamine D1 and D2 receptor stimulation. J. Pharmacol. Exp. Ther. 307(1), 386-94.
132. Jaber M., Jones S., Giros B., Caron M. G. (1997). The dopamine transporter: a crucial component regulating dopamine transmission. Mov. Disord. 12(5), 629-33.
133. Jellinger K. (1991). Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. Mol. Chem. Neuropathol. 14, 153-97.
134. Jones B., Moore R. (1977). Ascending projections of the locus coeruleus in the rat. II. Autoradiographic study. Brain Res. 127, 23-53.
135. Kandel E. R., Schwartz J. H., Jessell T. M. (2000). Principles of Neural Science, 4th ed. New York, NY: McGraw-Hill
136. Karlsson P., Farde L., Halldin C. (2000). Circadian rhythm in central D1-like dopamine receptors examined by PET. In: The 3rd International Symposium on functional Neuroreceptor Mapping; 2000; New York, NY: J. Neuroimaging.
137. Katz P. (1996). Neurons, networks, and motor behavior. Neuron. 16, 245-53.
138. Kawano Y., Kawasaki T., Kawazoe N. et al. (1990). Circadian variations of urinary dopamine, norepinephrine, epinephrine and sodium in normotensive and hypertensive subjects. Nephron 55(3), 277-82.
139. Kaynak D., Kiziltan G., Kaynak H., Benbir G., Uysal O. (2005). Sleep and sleepiness in patients with Parkinson's disease before and after dopaminergic treatment. Eur. J. Neurol. 12, 199-207.
140. Keating G., Rye D. (2003). Where you least expect it: dopamine in the pons aion of sleep and REM-sleep. Sleep 26, 788-9.
141. Khaldy H., Leon J., Escames G. et al. (2002). Circadian rhythms of dopamine and dihydroxyphenyl acetic acid in the mouse striatum: effects of pinealectomy and of melatonin treatment. Neuroendocrinology 75(3), 201-8.
142. Kiehn O., Kjaerulff O. (1996). Spatiotemporal characteristics of 5-HT and dopamine-induced rhythmic hindlimb activity in the in vitro neonatal rat. J. Neurophysiol. 75(4), 1472-82.
143. Kitai S. T., Shepard P. D., Callaway J. C., Scroggs R. (1999). Afferent modulation of dopamine neuron firing patterns. Curr. Opin. Neurobiol. 9(6), 690-7.
144. Korotkova T., Sergeeva O., Eriksson K., Haas H., Brown R. (2003). Excitation of ventral tegmental area dopaminergic and nondopaminergic neurons by orexins/hypocretins. J. Neurosci. 23, 7-11.
145. Krimer L. S., Muly E. C. III, Williams G. V., Goldman-Rakic P. S. (1998). Dopaminergic regulation of cerebral cortical microcirculation. Nat. Neurosci. 1(4), 286-9.
146. Krulich L. (1979). Central neurotransmitters and the secretion of prolactin, GH, LH and TSH. A. Rev. Physiol. 41, 603-15.
147. Kume K., Kume S., Park S. K., Hirsh J., Jackson F. R. (2005). Dopamine is a regulator of arousal in the fruit fly. J. Neurosci. 25(32), 7377-84.
148. Lagos P., Scorza C., Monti J. M. et al. (1998). Effects of the D3 preferring dopamine agonist pramipexole on sleep and waking, locomotor activity and striatal dopamine release in rats. Eur. Neuropsychopharmacol. 8(2), 113-20.
149. Lal S., Thavundayil J., Nair N. P. et al. (1981). Effect of sleep deprivation on dopamine receptor function in normal subjects. J. Neural Transm. 50(1), 39-45.
150. Lara-Lemus A., Drucker-Colin R., Mendez-Franco J., Palomero-Rivero M., Perez de la Mora M. (1998). Biochemical effects induced by REM sleep deprivation in naive and in D-amphetamine treated rats. Neurobiology 6(1), 13-22.
151. Lategan A., Marien M., Colpaert F. (1992). Suppression of nigrostriatal and mesolimbic dopamine release in vivo following noradrenaline depletion by DSP-4: a microdialysis study. Life Sci. 50, 995-9.
152. Lavia Fantini M., Gagnon J., Petit D. et al. (2003). Slowing of electroencephalogram in rapid eye movement sleep behavior disorder. Ann. Neurol. 53, 774-80.
153. Lavin A., Grace A. A. (1998). Dopamine modulates the responsivity of mediodorsal thalamic cells recorded in vitro. J. Neurosci. 18(24), 10566-78.
154. Lavoie B., Parent A. (1990). Immunohistochemical study of the serotoninergic innervation of the basal ganglia in the squirrel monkey. J. Comp. Neurol. 299, 1-16.
155. Lee R. S., Steffensen S. C., Henriksen S. J. (2001). Discharge profiles of ventral tegmental area GABA neurons during movement, anesthesia, and the sleep-wake cycle. J. Neurosci. 21(5), 1757-66.
156. Lejeune F., Millan M. (1999). Pindolol excites dopaminergic and adrenergic neurons, and inhibits serotonergic neurons, by activation of 5-HT1A receptors. Eur. J. Neurosci. 12, 3265-75.
157. Lemmer B., Berger T. (1978). Diurnal rhythm in the central dopamine turnover in the rat. Naunyn Schmiedebergs Arch. Pharmacol. 303(3), 257-61.
158. Lena I., Parrot S., Deschaux O. et al. (2005). Variations in the extracellular levels of dopamine, noradrenaline, glutamate, and aspartate across the sleep-wake cycle in the medial prefrontal cortex and nucleus accumbens of freely moving rats. J. Neurosci. Res. 81, 891-9.
159. Leng A., Mura A., Hengerer B., Feldon J., Ferger B. (2004). Effects of blocking the dopamine biosynthesis and of neurotoxic dopamine depletion with 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) on voluntary wheel running in mice. Behav. Brain Res. 154, 375-83.
160. Li Y., van den Pol A. (2005). Direct and indirect inhibition by catecholamines of hypocretin/orexin neurons. J. Neurosci. 25, 173-83.
161. Lindvall O., Bjorklund A. (1982). Neuroanatomy of central dopamine pathways: review of recent progress. In: M Keal, editor. Advances in Dopamine Research. Oxford and New York: Pergamon Press; pp. 297-311.
162. Liprando L., Miner L., Blakely R., Lewis D., Sesack S. (2004). Ultrastructural interactions between terminals expressing the norepinephrine transporter and dopamine neurons in the rat and monkey ventral tegmental area. Synapse 52, 233-44.
163. Lonstein J., Blaustein J. (2004). Immunoctyochemical investigation of nuclear progestin receptor expression within dopaminergic neurones of the female rat brain. J. Neuroendocrinol. 16, 534-43.
164. Lu J., Jhou T. C., Saper C. B. (2006). Identification of wake-active dopaminergic neurons in the ventral periaqueductal gray matter. J. Neurosci. 26(1), 193-202.
165. Luppi P. H., Aston-Jones G., Akaoka H., Chouvet G., Jouvet M. (1995). Afferent projections to the rat locus coeruleus demonstrated by retrograde and anterograde tracing with cholera-toxin B subunit and Phaseolus vulgaris leucoagglutinin. Neuroscience 65(1), 119-60.
166. Mandell A. J., Bullard W. P., Yellin J. B., Russo P. V. (1980). The influence of D-amphetamine on rat brain striatal reduced biopterin concentration. J. Pharmacol. Exp. Ther. 213(3), 569-74.
167. Manni R., Terzaghi M., Sartori I., Mancini F., Pacchetti C. (2004). Dopamine agonists and sleepiness in PD: a review of the literature and personal findings. Sleep Med. 5, 189-93.
168. Marin O., Smeets W. J., Gonzalez A. (1998). Evolution of the basal ganglia in tetrapods: a new perspective based on recent studies in amphibians. Trends Neurosci. 21(11), 487-94.
169. Martin J. (1978). Neural regulation of growth hormone secretion. Med. Clin. N. Am. 62, 327-36.
170. Maslowski R. J., Napier T. C. (1991). Dopamine D1 and D2 receptor agonists induce opposite changes in the firing rate of ventral pallidal neurons. Eur. J. Pharmacol. 200(1), 103-12.
171. Mathe J. M., Nomikos G. G., Blakeman K. H., Svensson T. H. (1999). Differential actions of dizocilpine (MK-801) on the mesolimbic and mesocortical dopamine systems: role of neuronal activity. Neuropharmacology 38(1), 121-8.
172. Matsumoto M., Kimura K., Fujisawa A. et al. (1981). Diurnal variations in monoamine contents in discrete brain regions of the Mongolian gerbil (Meriones unguiculatus). J. Neurochem. 37, 792-4.
173. McClung C., Sidiropoulou K., Vitaterna M. et al. (2005). Regulation of dopaminergic transmission and cocaine reward by the Clock gene. Proc. Natl. Acad. Sci. USA 102, 9377-81.
174. McGeer E., McGeer P. (1973). Some characteristics of brain tyrosine hydroxylase. In: Mandel A., editor. New Concepts in Neurotransmitter Regulation. New York: Plenum Press; pp. 53-68.
175. McKeith I. G., Ballard C. G., Perry R. H. et al. (2000). Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies [In Process Citation]. Neurology 54(5), 1050-8.
176. Megaw P., Boelen M., Morgan I., Boelen M. (2006). Diurnal patterns of dopamine release in chicken retina. Neurochem. Intl. 48, 17-23.
177. Mejias-Aponte C., Zhu Y., Aston-Jones G. S. (2004). Noradrenergic innervation of midbrain dopamine neurons: prominent inputs from A1 and A2 Cell groups. In: Society for Neuroscience Annual Meeting; Abstract No. 465.464.
178. Mignot E., Taheri S., Nishino S. (2002). Sleeping with the hypothalamus: emerging therapeutic targets for sleep disorders. Nat. Neurosci. 5 (Suppl), 1071-5.
179. Miller A., Blaha C. (2004). Nigrostriatal dopamine release modulated by mesopontine muscarinic receptors. NeuroReport 15, 1805-8.
180. Miller E., Nieburg H. (1973). Amphetamines. Valuable adjunct in treatment of Parkinsonism. NY State J. Med. 73, 2657-61.
181. Miller J., Farber J., Gatz P., Roffwarg H., German D. (1983). Activity of mesencephalic dopamine and non-dopamine neurons across stages of sleep and waking in the rat. Brain Res. 273, 133-41.
182. Missale C., Nash S. R., Robinson S. W., Jaber M., Caron M. G. (1998). Dopamine receptors: from structure to function. Physiol. Rev. 78(1), 189-225.
183. Momiyama T., Sim J. A. (1996). Modulation of inhibitory transmission by dopamine in rat basal forebrain nuclei: activation of presynaptic D1-like dopaminergic receptors. J. Neurosci. 16(23), 7505-12.
184. Monti J., Hawkins M., Jantos H., D'Angelo L., Fernandez M. (1988). Biphasic effects of dopamine D-2 receptor agonists on sleep and wakefulness in the rat. Psychopharmacology 95, 395-400.
185. Monti J. M., Fernandez M., Jantos H. (1990). Sleep during acute dopamine D1 agonist SKF 38393 or D1 antagonist SCH 23390 administration in rats. Neuropsychopharmacology 3(3), 153-62.
186. Monti J. M. (1989). Effects of the selective dopamine D2 receptor agonist, quinpirole on sleep and wakefulness in the rat. Eur. J. Pharmacol. 169, 61-6.
187. Moukhles H., Bosler O., Bolam J. et al. (1997). Quantitative and morphometric data indicate precise cellular interactions between serotonin terminals and postsynaptic targets in rat substantia nigra. Neuroscience 76, 1159-71.
188. Muller E. (1973). Nervous control of growth hormone secretion. Neuroendocrinology 11, 338-69.
189. Munsch T., Yanagawa Y., Obata K., Pape H. (2005). Dopaminergic control of local interneuron activity in the thalamus. Eur. J. Neurosci. 21, 290-4.
190. Naber D., Wirz-Justice A., Kafka M. S., Wehr T. A. (1980). Dopamine receptor binding in rat striatum: ultradian rhythm and its modification by chronic imipramine. Psychopharmacology (Berl). 68(1), 1-5.
191. Nagatsu I. (1995). Tyrosine hydroxylase: human isoforms, structure and regulation in physiology and pathology. Essays Biochem. 30, 15-35.
192. Nagatsu T., Levitt M., Udenfriend S. (1964). Tyrosine hydroxylase, the initial step in norepinephrine synthesis. J. Biol. Chem. 239, 2910-17.
193. Nagayama H., Takagi A., Nakamura E., Yoshida H., Takahashi R. (1978). Circadian susceptibility rhythm to apomorphine in the brain. Commun. Psychopharmacol. 2(4), 301-10.
194. Nakamura T., Uramura K., Nambu T. et al. (2000). Orexin-induced hyperlocomotion and stereotypy are mediated by the dopaminergic system. Brain Res. 873(1), 181-7.
195. Nakashima A., Mori K., Suzuki T. et al. (1999). Dopamine inhibition of human tyrosine hydroxylase type I is controlled by the specific portion in the N-terminus of the enzyme. J. Neurochem. 72, 2145-53.
196. Napier T. C., Potter P. E. (1989). Dopamine in the rat ventral pallidum/substantia innominata: biochemical and electrophysiological studies. Neuropharmacology 28(7), 757-60.
197. Nicola S., Surmeier J., Malenka R. (2000). Dopaminergic modulation of neuronal excitability in the striatum and nucleus accumbens. A. Rev. Neurosci. 23, 185-215.
198. Nishino S., Arrigoni J., Valtier D. et al. (1991). Dopamine D2 mechanisms in canine narcolepsy. J. Neurosci. 11, 2666-71.
199. Nishino S., Mao J., Sampathkumaran R., Shelton J., Mignot E. (1998). Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants. Sleep Res. Online 1(1), 49-61.
200. Nunes G., Jr, Tufik S., Nobrega N. (1994). Autoradiographic analysis of D1 and D2 dopaminergic receptors in rat brain after paradoxical sleep deprivation. Brain Res. Bull. 34(5), 453-6.
201. Nygaard T., Marsden C., Duvoisin R. (1988). Dopa-responsive dystonia. Adv. Neurol. 50, 377-84.
202. Nygaard T. (1993). Dopa-responsive dystonia. Delineation of the clinical syndrome and clues to pathogenesis. Adv. Neurol. 1993, 577-85.
203. O'Neill R. D., Fillenz M. (1985). Simultaneous monitoring of dopamine release in rat frontal cortex, nucleus accumbens and striatum: effect of drugs, circadian changes and correlations with motor activity. Neuroscience 16(1), 49-55.
204. Olijslagers J., Werkman T., McReary A. et al. (2004). 5-HT2 receptors differentially modulate dopamine-mediated auto-inhibition in A9 and A10 midbrain areas of the rat. Neuropharmacology 46, 504-10.
205. Olive M. F., Seidel W. F., Edgar D. M. (1998). Compensatory sleep responses to wakefulness induced by the dopamine autoreceptor antagonist (-)DS121. J. Pharmacol. Exp. Ther. 285(3), 1073-83.
206. Ongini E., Bonizzoni E., Ferri N., Milani S., Trampus M. (1993). Differential effects of dopamine D1 and D2 receptor antagonist antipsychotics on sleep-wake patterns in the rat. J. Pharmacol. Exp. Ther.
207. Ornstein K., Milon H., McRae-Degueurce A. et al. (1987). Biochemical and radioautographic evidence for dopaminergic afferents of the locus coeruleus originating in the ventral tegmental area. J. Neural Transm. 70(3-4), 183-91.
208. Overeem S., van Hilten J. J., Ripley B., Mignot E., Nishino S., Lammers G. J. (2002). Normal hypocretin-1 levels in Parkinson's disease patients with excessive daytime sleepiness. Neurology 58(3), 465-8.
209. Owasoyo J. O., Walker C. A., Whitworth U. G. (1979). Diurnal variation in the dopamine level of rat brain areas: effect of sodium phenobarbital. Life Sci. 25(2), 119-22.
210. Pacchetti C., Martignoni E., Terzaghi M. et al. (2003). Sleep attacks in Parkinson's disease: a clinical and polysomnographic study. Neurol. Sci. 24, 195-6.
211. Parkes J. D., Tarsy D., Marsden C. D. et al. (1975). Amphetamines in the treatment of Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 38(3), 232-7.
212. Paulson P. E., Robinson T. E. (1994). Relationship between circadian changes in spontaneous motor activity and dorsal versus ventral striatal dopamine neurotransmission assessed with on-line microdialysis. Behav. Neurosci. 108(3), 624-35.
213. Perlow M. J., Gordon E. K., Ebert M. E., Hoffman H. J., Chase T. N. (1977). The circadian variation in dopamine metabolism in the subhuman primate. J. Neurochem. 28(6), 1381-3.
214. Pi X., Voogt J., Grattan D. (2002). Detection of prolacting receptor mRNA in the corpus striatum and substantia nigra of the rat. J. Neurosci. Res. 67, 551-8.
215. Porzgen P., Park S. K., Hirsh J., Sonders M. S., Amara S. G. (2001). The antidepressant-sensitive dopamine transporter in Drosophila melanogaster: a primordial carrier for catecholamines. Mol. Pharmacol. 59(1), 83-95.
216. Ramsey A., Fitzpatrick P. (1998). Effects of phosphorylation of serine 40 of tyrosine hydroxylase on binding of catecholamines: evidence for a novel regulatory mechanism. Biochemistry 37, 8980-6.
217. Ramsey A., Hillas P., Fitzpatrick P. (1996). Characterization of the active site iron in tyrosine hydroxylase redox states of the iron. J. Biol. Chem. 271, 24395-400.
218. Razmy A., Lang A., Shapiro C. (2004). Predictors of impaired daytime sleep and wakefulness in patients with Parkinsons disease treated with older (ergot) vs newer (nonergot) dopamine agonists. Arch. Neurol. 61, 97-102.
219. Reid M., Tafti M., Nishino S. et al. (1996). Local administration of dopaminergic drugs into the ventral tegmental area modulates cataplexy in the narcoleptic canine. Brain Res. 133, 83-100.
220. Ribelayga C., Wang Y., Mangel S. (2004). A circadian clock in the fish retina regulates dopamine release via activation of melatonin receptors. J. Physiol. 554(2), 467-82.
221. Roth T., Rye D., Borchert L. et al. (2003). Assessment of sleepiness and unintended sleep in Parkinson's disease patients taking dopamine agonists. Sleep Med. 4, 275-80.
222. Rub U., Del Tredici K., Schultz C. et al. (2002). Parkinson's disease: the thalamic components of the limbic loop are severely impaired by alpha-synuclein immunopositive inclusion body pathology. Neurobiol. Aging 23, 245-54.
223. Rye D., Bliwise D. (2004). Movement disorders specific to sleep and the nocturnal manifestations of waking movement disorders. In: Watts R., Koller W., editors. Movement Disorders: Neurologic Principles and Practice, 2nd edn. New York, NY: McGraw-Hill. pp. 855-90.
224. Rye D., Bliwise D. (1997). Movement disorders specific to sleep and the nocturnal manifestations of waking movement disorders. In: Watts R., Koller W., editors. Movement Disorders: Neurologic Principles and Practice. New York: McGraw-Hill; pp. 687-713.
225. Rye D., Daley J., Freeman A., Bliwise D. (2003). Daytime sleepiness and sleep attacks in idiopathic parkinson's disease. In: Bedard M-A., Agid Y., Chouinard S. et al. editors. Mental and Behavioral Dysfunction in Movement Disorders. Totawa, NJ: Humana Press; pp. 527-38.
226. Rye D., Iranzo A. (2005). The nocturnal manifestations of waking movement disorders: focus on Parkinson's disease. In: Guilleminault C., editor. Handbook of Clinical Neurophysiology: Clinical Neurophysiology of Sleep Disorders. Philadelphia, PA: Elsevier BV; pp. 263-72.
227. Rye D., Johnston L., Watts R., Bliwise D. (1999). Juvenile Parkinson's disease with REM behavior disorder, sleepiness and daytime REM-onsets. Neurology 53, 1868-70.
228. Rye D. (1997). Contributions of the pedunculopontine region to normal and altered REM sleep. Sleep 20(9), 757-88.
229. Rye D. (2006). Excessive daytime sleepiness and unintended sleep in Parkinson's disease. Curr. Neurol. Neurosci. Rep. 6, 169-76.
230. Rye D. (2003). Modulation of normal and pathologic motoneuron activity during sleep. In: Chokroverty S., Hening W., Walters A., editors. Sleep and Movement Disorders. Philadelphia, PA: Butterworth-Heinemann; pp. 94-119.
231. Rye D. (2004b). Parkinson's disease and RLS: the dopaminergic bridge. Sleep Med. 5, 317-28.
232. Rye D. (2004a). The two faces of Eve: dopamine's modulation of wakefulness and sleep. Neurology 63 (suppl. 3), S2-S7.
233. Rye D. B., Bliwise D. L., Dihenia B., Gurecki P. (2000). FAST TRACK: daytime sleepiness in Parkinson's disease. J. Sleep Res. 9(1), 63-9.
234. Rye D. B., Jankovic J. (2002). Emerging views of dopamine in modulating sleep/wake state from an unlikely source: PD. Neurology 58(3), 341-6.
235. Sakamoto K., Liu C., Kasamatsu M. et al. (2005). Dopamine regulates melanopsin mRNA expression in intrinsically photoresponsive retinal ganglion cells. Eur. J. Neurosci. 22, 3129-36.
236. Sakata M., Sei H., Toida K. et al. (2002). Mesolimbic dopaminergic system is involved in diurnal blood pressure regulation. Brain Res. 928(1-2), 194-201.
237. Sanchez-Gonzalez M., Garcia-Cabezas M., Rico B., Cavada C. (2005). The primate thalamus is a key target for brain dopamine. J. Neurosci. 25, 6076-83.
238. Sautel F., Griffon N., Levesque D. et al. (1995). A functional test identifies dopamine agonists selective for D3 versus D2 receptors. Neuroreport 6, 329-32.
239. Schapira A. (2004). Excessive daytime sleepiness in Parkinson's disease. Neurology 63(8 Suppl. 3), S24-7.
240. Schenck C., Bundlie S., Mahowald M. (2003). REM behavior disorder (RBD): delayed emergence of parkinsonism or dementia in 65% of older men initially diagnosed with idiopathic RBD, and an analysis of the minimum and maximum tonic and/or phasic electromyographic abnormalities found during REM sleep. Sleep 26(Suppl.), A316.
241. Scheving L. E., Harrison W. H., Gordon P., Pauly J. E. (1968). Daily fluctuation (circadian and ultradian) in biogenic amines of the rat brain. Am. J. Physiol. 214(1), 166-73.
242. Seutin V. (2005). Dopaminergic neurones: much more than dopamine? Br. J. Pharmacol. 146, 167-9.
243. Sherman S. M., Guillery R. W. (2001). Exploring the Thalamus. San Diego, CA: Academic Press.
244. Shouse M. N., Staba R. J., Saquib S. F., Farber P. R. (2000). Monoamines and sleep: microdialysis findings in pons and amygdala. Brain Res. 860(1-2), 181-9.
245. Silber M. H., Rye D. B. (2001). Solving the mysteries of narcolepsy. Neurology 56, 1616-18.
246. Skagerberg G., Bjorklund A., Lindvall O., Schmidt R. H. (1982). Origin and termination of the diencephalo-spinal dopamine system in the rat. Brain Res. Bull. 9(1-6), 237-44.
247. Skagerberg G., Lindvall O. (1985). Organization of diencephalic dopamine neurones projecting to the spinal cord in the rat. Brain Res. 342(2), 340-51.
248. Smeets W., Gonzalez A. (2000). Catecholamine systems in the brain of vertebrates: new perspectives through a comparative approach. Brain Res. Brain Res. Rev. 33, (308-79).
249. Smiley J., Subramanian M., Mesulam M-M. (1999). Monoaminergic-cholinergic interactions in the primate basal forebrain. Neuroscience 93, 817-29.
250. Smith A. D., Olson R. J., Justice J. B., Jr. (1992). Quantitative microdialysis of dopamine in the striatum: effect of circadian variation. J. Neurosci. Meth. 44(1), 33-41.
251. Sokoloff P., Andrieux M., Besancon R. et al. (1992). Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor. Eur. J. Pharmacol. 225, 331-7.
252. Sowers J. R., Vlachakis N. (1984). Circadian variation in plasma dopamine levels in man. J. Endocrinol. Invest. 7(4), 341-5.
253. Stanley M., Traskman-Bendz L., Dorovini-Zis K. (1985). Correlations between aminergic metabolites simultaneously obtained from human CSF and brain. Life Sci. 37(14), 1279-86.
254. Steenhard B., Besharse J. (2000). Phase shifting the retinal circadian clock: xPer2 mRNS induction by light and dopamine. J. Neurosci. 20, 8572-7.
255. Steinfels G., Heym J., Strecker R., Jacobs B. (1983). Behavioral correlates of dopaminergic unit activity in freely moving cats. Brain Res. 258, 217-28.
256. Steriade M., Pare D., Datta S., Oakson G., Dossi R. C. (1990). Different cellular types in mesopontine cholinergic nuclei related to ponto-geniculo-occipital waves. J. Neurosci. 10(8), 2560-79.
257. Stevens S., Comella C., Stepanski E. (2004). Daytime sleepiness and alertness in patients with Parkinson disease. Sleep 27, 967-72.
258. Strogatz S. H., Kronauer R. E., Czeisler C. A. (1987). Circadian pacemaker interferes with sleep onset at specific times each day: role in insomnia. Am. J. Physiol. 253(1), R172-8.
259. Takada M. (1993). Widespread dopaminergic projections of the subparafascicular thalamic nucleus in the rat. Brain Res. Bull. 32, 301-9.
260. Tan E. K., Lum S. Y., Fook-Chong S. M. C. et al. (2002). Evaluation of somnolence in Parkinson's disease: comparison with age and sex matched controls. Neurology 58(3), 465-8.
261. Tassin J., Lavielle S., Herve D. et al. (1979). Collateral sprouting and reduced activity of the rat mesocortical dopaminergic neurons after selective destruction of the ascending noradrenergic bundles. Neuroscience 4, 1569-82.
262. Trampus M., Ferri N., Adami M., Ongini E. (1993). The dopamine D1 receptor agonists, A68930 and SKF 38393, induce arousal and suppress REM sleep in the rat. Eur. J. Pharmacol. 235, 83-7.
263. Trampus M., Ferri N., Monopoli A., Ongini E. (1991). The dopamine D1 receptor is involved in the regulation of REM sleep in the rat. Eur. J. Pharmacol. 194, 189-94.
264. Trulson M., Preussler D. (1984). Dopamine-containing ventral tegmental area neurons in freely moving cats: activity during the sleep-waking cycle and effects of stress. Exp. Neurol. 83, 367-77.
265. Trulson M. E. (1985). Simultaneous recording of substantia nigra neurons and voltammetric release of dopamine in the caudate of behaving cats. Brain Res. Bull. 15(2), 221-3.
266. Tufik S., Lindsey C. J., Carlini E. A. (1978). Does REM sleep deprivation induce a supersensitivity of dopaminergic receptors in the rat brain? Pharmacology 16(2), 98-105.
267. Turner R., D'Amato C., Chervin R., (2000). Blaivas M. The pathology of REM-sleep behavior disorder with comorbid Lewy body dementia. Neurology 55, 1730-2.
268. Tzschentke T., Schmidt W. (2000). Functional relationship among medial prefrontal cortex, nucleus accumbens, and ventral tegmental area in locomotion and reward. Crit. Rev. Neurobiol. 14, 131-42.
269. Ulivelli M., Rossi S., Lombard C. et al. (2002). Polysomnographic characterization of pergolide-induced "sleep attacks" in an idiopathic PD patient. Neurology 58(3), 462-5.
270. Uramura K., Funahashi H., Muroya S. et al. (2001). Orexin-a activates phospholipase C- and protein kinase C-mediated Ca2+ signaling in dopamine neurons of the ventral tegmental area. NeuroReport 12, 1885-9.
271. Urbain N., Gervasoni D., Souliere F. et al. (2000). Unrelated course of subthalamic nucleus of globus pallidus neuronal activities across vigilance states in the rat. Eur. J. Neurosci. 12, 3361-74.
272. Ventura R., Cabib S., Alcaro A., Orsini C., Puglisi-Allegra S. (2003). Norepinephrine in the prefrontal cortex is critical for amphetamine-induced reward and mesoaccumbens dopamine release. J. Neurosci. 23, 1879-85.
273. Watanabe S., Seeman P. (1984). D2 dopamine receptor density in rat striatum over 24 hours: lack of detectable changes. Biol. Psychiatry 19(8), 1249-53.
274. Wetter T., Collado-Seidel V., Pollmacher T., Yassouridis A., Trenkwalder C. (2000). Sleep and periodic leg movement patterns in drug-free patients with Parkinson's disease and multiple system atrophy. Sleep 23(3), 361-7.
275. Whittaker J., Morcol T., Patrickson J. (1997). Circadian plasticity in dopaminergic parameters in the rat substantia nigra. Soc. Neurosci. Abstr. 23(80.2), 190.
276. Williams S. M., Goldman-Rakic P. S. (1998). Widespread origin of the primate mesofrontal dopamine system. Cereb. Cortex 8(4), 321-45.
277. Wisor J., Nishino S., Sora I. et al. (2001). Dopaminergic role in stimulant-induced wakefulness. J. Neurosci. 21(5), 1787-94.
278. Witkovsky P. (2004). Dopamine and retinal function. Doc. Ophthalmol. 108, 17-40.
279. Xuereb J. H., Perry R. H., Candy J. M. et al. (1991). Nerve cell loss in the thalamus in Alzheimer's disease and Parkinson's disease. Brain 114, 1363-79.
280. Yamanaka A., Muraki Y., Ichiki K. et al. (2006). Orexin neurons are directly and indirectly regulated by catecholamines in a complex manner. J. Neurophysiol. Epub-ahead of print.
281. Zeitzer J., Lopez-Rodriguez F., Behnke E. et al. (2001). Serotonin and dopamine in the human cortex and limbic system during a 40h sleep deprivation challenge. Sleep 24, A76.
282. Zwicker A., Calil H. (1986). The effects of REM sleep deprivation on striatal dopamine receptor sites. Pharmacol. Biochem. Behav. 24, 809-12.